Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan

Akira Morimoto, Yoko Shioda, Toshihiko Imamura, Hirokazu Kanegane, Takashi Sato, Kazuko Kudo, Shinichiro Nakagawa, Hisaya Nakadate, Hisamichi Tauchi, Asahito Hama, Masahiro Yasui, Yoshihisa Nagatoshi, Akitoshi Kinoshita, Ryosuke Miyaji, Tadashi Anan, Miharu Yabe, Junji Kamizono

研究成果: Article査読

26 被引用数 (Scopus)

抄録

Background: Several studies have suggested that Langerhans cell histiocytosis (LCH) is responsive to treatment with bisphosphonates (BPs). However the efficacy and safety of BPs therapy for childhood LCH is unknown. Procedure: Data on children with LCH who had received BPs therapy were collected retrospectively from hospitals participating in the Japanese Pediatric Leukemia/Lymphoma Study Group. Results: Twenty-one children with histologically proven LCH were identified. Of these, the case histories of 16 children who had been treated with pamidronate (PAM) for disease reactivation were analyzed in detail. The median post-PAM therapy follow-up period was 2.8 years (range: 0.9-9.3 years). The median age at commencement of PAM therapy was 9.4 years (range: 2.3-15.0 years). All children had one or more bone lesions but none had risk organ (RO) involvement. In the majority of the children, six courses of PAM were administered at a dose of 1.0 mg/kg/course at 4-week intervals. In 12 of the 16 children, all active lesions including lesions of the skin (n = 3) and soft tissues (n = 3) resolved. Of these children, eight children had no active disease for a median of 3.3 years post-PAM therapy (range: 1.8-9.3 years). Progression-free survival (PFS) was 56.3 ± 12.4% at 3 years. PFS was significantly higher in children with a first reactivation compared with children experiencing a second or subsequent reactivation. Conclusions: PAM may be an effective treatment for reactivated LCH with bone lesions. A prospective trial of the efficacy of PAM in recurrent pediatric LCH is warranted.

本文言語English
ページ(範囲)110-115
ページ数6
ジャーナルPediatric Blood and Cancer
56
1
DOI
出版ステータスPublished - 01-2011
外部発表はい

All Science Journal Classification (ASJC) codes

  • 小児科学、周産期医学および子どもの健康
  • 血液学
  • 腫瘍学

フィンガープリント

「Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル